Sarepta: We’ve Seen This Before
May 26, 2016 at 10:52 AM EDT
Yesterday, the FDA delayed its decision on Sarepta Therapeutics' ( SRPT ) Duchenne muscular dystrophy treatment, a decision that was greeted with delight by the market. In a note released yesterday, SunTrust's Edward Nash and team joined the growing chorus of analysts who don't expect the delay to lead to an approval , citing BioMarin Pharmaceuticals ( BMRN ) experience: